A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir
NCT03198884 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20
Last updated 2020-09-01
Summary
A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir
Conditions
Interventions
- DRUG
-
Darunavir 800 MG, Norvir 100 MG, Dolutegravir 50 MG
Sponsors & Collaborators
-
Janssen Scientific Affairs, LLC
collaborator INDUSTRY -
Southern Illinois Healthcare Foundation
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-01-01
- Primary Completion
- 2018-04-18
- Completion
- 2018-05-01
- FDA Drug
- Yes
More Related Trials
-
Evaluation of Low-dose Darunavir in a Switch Study
NCT02671383 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy Study of Substitution of Darunavir/Ritonavir (DRV/r) for Dual-boosted Protease Inhibitors
NCT00543101 ·Status: COMPLETED ·Phase: PHASE4
-
Study Evaluating the Efficacy of a Reduced Dose Atazanavir in HIV-1-infected Patients
NCT02473328 ·Status: COMPLETED ·Phase: PHASE2
-
Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART
NCT00038532 ·Status: COMPLETED ·Phase: PHASE2
-
Darunavir/Ritonavir and Rosuvastatin Pharmacokinetic Study
NCT00885495 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)
NCT02429791 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors
NCT00004580 ·Status: COMPLETED ·Phase: PHASE1
-
Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients
NCT00677300 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult Subjects
NCT01467531 ·Status: COMPLETED ·Phase: PHASE1
-
TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV
NCT01281813 ·Status: COMPLETED ·Phase: PHASE3
-
A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen
NCT00135343 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Study to Evaluate the Efficacy and Safety of Lopinavir/Ritonavir Monotherapy Versus Darunavir/Ritonavir Monotherapies as Simplification Switching Strategies of PI/NNRTI-Triple Therapy Based-Regimens
NCT00994344 ·Status: COMPLETED ·Phase: PHASE4
-
Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients
NCT01332227 ·Status: COMPLETED ·Phase: PHASE4
-
Study in Healthy Males to Measure Darunavir and Etravirine in Blood, Seminal Fluid, and Rectal Tissue
NCT00855088 ·Status: COMPLETED ·Phase: PHASE1
-
The Dolutegravir Antiretroviral Mono-Therapy for HIV Trial
NCT02401828 ·Status: COMPLETED ·Phase: PHASE4
-
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
NCT01448707 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients
NCT01199939 ·Status: COMPLETED ·Phase: PHASE2
-
ABT-378/Ritonavir and Efavirenz in HIV-Infected Patients Who Have Taken More Than One Protease Inhibitor in the Past
NCT00004582 ·Status: COMPLETED ·Phase: PHASE2
-
Dose Finding Confirmation of Atazanavir With Ritonavir and Efavirenz (ATV/RTV + EFV) in Healthy Subjects
NCT00357188 ·Status: COMPLETED ·Phase: PHASE1
-
Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)
NCT02422797 ·Status: COMPLETED ·Phase: PHASE3
-
Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine
NCT04538040 ·Status: COMPLETED ·Phase: PHASE4
-
Microboosting of Atazanavir 300 mg With 50 mg Versus 100mg Ritonavir Daily in HIV-infected Patients: a Pharmacokinetic Study
NCT02034838 ·Status: COMPLETED ·Phase: PHASE1
-
Exploratory Study of Tipranavir and Ritonavir in Multiple Protease Inhibitor-experienced HIV Patients
NCT02238314 ·Status: COMPLETED ·Phase: PHASE2
-
Drug Interaction Study of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK2248761 PK and CYP450 Probe Drugs
NCT00920088 ·Status: COMPLETED ·Phase: PHASE1
-
TMC114-TiDP3-C181: Study to Assess the Pharmacokinetics of Darunavir (DRV) With Different Doses of Ritonavir in Healthy Volunteers.
NCT00744887 ·Status: COMPLETED ·Phase: PHASE1